Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tremelimumba

- PMLiVE

EORTC and Pierre Fabre launch phase 3 trial for melanoma

Over 300,000 new cases of melanoma are diagnosed globally each year

- PMLiVE

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion

- PMLiVE

Keytruda gains eighth FDA approval this year

Merck’s megablockbuster Keytruda has returned to its roots with a new indication in melanoma, the therapy area where it was first approved seven years ago

- PMLiVE

AZ to seek approval for “long-acting” COVID-19 antibodies

AZD7442 significantly reduced the risk of developing symptomatic COVID-19 in phase 3 trial and is a one-dose treatment that can be given via an intramuscular injection

- PMLiVE

Great creative is effective creative. And effective creative is affective creative

Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft...

Blue Latitude Health

Using Healthtech to Deliver Better Patient Outcomes

Peter Birch, General Manager (Asia Pacific) at MetaOptima Technologies & host of the “Talking HealthTech Podcast.” joins us to discuss a whole range of topics, including Peter’s professional journey and the...

Impetus Digital

Roche Basel Switzerland

Roche’s Tecentriq combo scores FDA approval for melanoma

Drug approved for patients with BRAF protein mutations

- PMLiVE

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

- PMLiVE

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech

AstraZeneca AZ

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

Filing due later this year

AstraZeneca AZ

AZ signs $20m deal with Seres for microbiome project

Shares in Seres shot up 25% after the deal was announced

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links